Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Key Highlights
- ➤IOP fell from 22.32 to 14.05 mmHg after 24 months
- ➤Topical IOP-lowering medications declined from 2.96 to 2.38
- ➤Treatment success reached 86% in POAG and 81% in PACG eyes
- ➤No complications or visual-acuity reductions were reported during follow-up
- ➤Iridex MicroPulse TLT study included 84 eyes from 53 patients
Expert Statements
Michele Lanza, Lead author of the study, Università della Campania Luigi Vanvitelli
“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced disease.”
Michele Lanza, Lead author of the study, Università della Campania Luigi Vanvitelli
“The findings suggest that MicroPulse TLT may have a role earlier in the glaucoma treatment continuum than has traditionally been considered.”
Patrick Mercer, President and Chief Executive Officer of Iridex
“We are encouraged by the sustained outcomes reported in this study and the growing body of clinical evidence supporting MicroPulse TLT.”
Patrick Mercer, President and Chief Executive Officer of Iridex
“These findings further reinforce our commitment to advancing laser-based treatment options for patients with glaucoma.”
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse(®) Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.
“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced disease,” said Michele Lanza, MD, lead author of the study. “The findings suggest that MicroPulse TLT may have a role earlier in the glaucoma treatment continuum than has traditionally been considered.”
Get started
Create a free account to read the full story.